Free CME

Primary care clinicians and endocrinologists play a critical role in identifying and managing metabolic dysfunction-associated steatohepatitis (MASH) before it progresses. Results from a Med-IQ survey, however, revealed that approximately half of the respondents screen only 50% or fewer of their patients with obesity or type 2 diabetes. Patients with these conditions or other risk factors, such as metabolic syndrome, dyslipidemia, or elevated liver enzymes, should be screened using noninvasive tools like FIB-4, transient elastography (FibroScan), ELF, or VCTE.

Although lifestyle modification remains the cornerstone of treatment, pharmacologic options such as GLP-1 receptor agonists, pioglitazone, and resmetirom may be appropriate based on individual risk profiles. Most patients can be effectively managed in primary care or endocrinology settings, with hepatology referral recommended for patients with a high risk of advanced fibrosis.

Includes eleven online, self-learning activities:

• The state of prostate cancer treatment: advances in approach for advanced disease –  (1 hr CE) ACCME ACPE MOC
• Ongoing challenges and optimal approaches in the management of metastatic colorectal cancer (mCRC) – (1 hr CE) ACCME ACPE MOC
• Advanced systemic mastocytosis: from recognition to treatment (Tsewang Tashi MD) – (1 hr CE) ACCME ACPE MOC
• Pancreatic Cancer: Updates from the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting – (0.75 hr CE) ACCME ACPE MOC
• Metastatic urothelial carcinoma (mUC): Updates from the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (Waddah Arafat MD) – (0.75 hr CE) ACCME ACPE MOC
• Taking the next step in the management of relapsed or refractory follicular lymphoma (Eric Tam MD) – (1 hr CE) ACCME ACPE MOC
• Initial- and later-line treatment considerations in advanced renal cell carcinoma (RCC) – (1 hr CE) ACCME ACPE MOC
• Treatment considerations in relapsed or refractory chronic lymphocytic leukemia (R/R CLL): evolving approaches to an evolving disease landscape – (1 hr CE) ACCME ACPE MOC
• Contemporary treatment approaches in the management of chronic graft-versus-host disease (GVHD) – (1 hr CE) ACCME ACPE MOC
• Hitting management strategies of metastatic nasopharyngeal carcinoma on the nose – (1 hr CE) ACCME ACPE MOC
• Advanced hepatocellular carcinoma (HCC) including updates from the European Society for Medical Oncology (ESMO) 2023 – (0.75 hr CE) ACCME ACPE MOC

Target Audience: HCPs including: medical oncologists, oncology surgeons, and pathologists; physicians assistants, nurse practitioners, and pharmacists specializing in oncology, hematology, gastroenterology, urology, with some overlap in otolaryngology, transplant medicine, allergy/immunology, nephrology, and hepatology

Early identification of atypical motor patterns is crucial for timely intervention and optimizing developmental outcomes in infants. A simple yet effective method for assessing these patterns involves observing the baby during a 30-second, 4-position exam. This examination includes careful observation of the infant in the following positions:

* Supine: Note posture, spontaneous movements, and interaction with the environment.

* Horizontal Suspension: Observe head control, trunk extension, and limb movements against gravity.

* Pull to Sit: Assess head lag, trunk activation, and ability to assist with the movement.

* Prone: Evaluate head lifting, weight-bearing through the arms, and early mobility attempts. Gain valuable insights and download resources through this complimentary CME/CE course

Target Audience: Neurologists

In this accredited activity, expert faculty, Adjoa Anyane‐Yeboa, MD, MPH, and Ugo Iroku, MD, MHS, dive into the issue of healthcare disparities in inflammatory bowel disease (IBD).

Healthcare disparities disproportionately affect minoritized and low-income groups, contributing to poor health outcomes. Patient-provider distrust, knowledge gaps, and lack of shared decision making contribute to health disparities in these patient groups and influence disease outcomes. It is critical for clinicians to understand the social determinants of health impacting IBD patient care and develop strategies to reduce disparities. In addition, implicit bias significantly affects clinician-patient interaction, as well as diagnosis and treatment decisions. Once clinicians are made aware of their implicit biases, they must work to overcome them and foster open communication with patients to reduce disparities and improve patient care.

In this 1-hour (chapter-based) presentation, join a primary care practitioner and an obesity specialist as they navigate real-world conversations about weight management. Explore effective pharmacologic options and gain confidence in initiating weight loss discussions.

Includes six online, self-learning activities: 

• Getting to what’s behind the itch: exploring the root causes and treatment strategies for atopic dermatitis – (1 hr CE) ACCME ACPE MOC 
• Tackling a sore subject: best practices in the identification and management of psoriatic arthritis (PsA) – (1 hr CE) ACCME ACPE MOC
• A critical appraisal of present and emerging management approaches to moderate to severe plaque psoriasis in adults: going beyond skin-deep –  (1.25 hr CE) ACCME ACPE MOC
• Spotlight on actinic keratosis: updates in practice and treatment optimization – (1 hr CE) ACCME ACPE MOC
• Recognition and management of epidermolysis bullosa: what the clinician needs to know – (1 hr CE) ACCME ACPE MOC
• Present and novel approaches in the medical management of generalized pustular psoriasis: balancing out the therapeutic landscape  (1 hr CE) ACCME ACPE MOC

Target Audience: Physicians focusing on Allergy, Dermatology, Rheumatology

Target Audience: Neurologists

In this 1-hour presentation, Dr. Charles Vega discusses the science behind multicancer early detection (MCED) testing and explores the benefits and limitations of MCED tests available for clinical use and undergoing investigation in clinical trials. Faculty also share practical clinical information on integrating MCED testing in current workflows, including identifying patients who are appropriate candidates for MCED testing, addressing patient concerns, and interpreting results. A guide to discussing MCED testing with patients is also provided.

In this accredited CME/CNE activity, cardiologist Dr. Matthew Martinez reviews key considerations and updates in the diagnosis and management of hypertrophic cardiomyopathy (HCM). Specifically, he explores the disease burden and the dire consequences of undiagnosed HCM, the difficulty in diagnosing HCM including lack of symptoms or presence of nonspecific symptoms, best practices for ordering echocardiograms, and guideline recommendations for treatment, including mavacamten. The informational session also discusses communicating with patients and caregivers/families.

This on-demand webinar provides a comprehensive overview of Pain Reprocessing Therapy, Emotional Awareness and Expression Therapy, and related approaches. Led by Yoni K. Ashar, PhD, this course explores the key distinctions between pain recovery therapies and traditional pain management, offering practical tools to help patients achieve lasting relief.

Physicians, psychologists, and healthcare professionals will benefit from this evidence-based training, earning 1 CME or CEU upon completion.

Target Audience: Physicians focusing on Allergy or Dermatology

Target Audience: Healthcare professionals specializing in colon and rectal surgery, family medicine, internal medicine, gastroenterology, oncology, pain management, palliative care, primary care, proctology, and other clinicians who treat patients suffering from gastrointestinal disorders.

Target Audience: Physicians focusing on Infectious Diseases. 

In this online, self-learning activity:

Alpha-mannosidosis (AM) is a rare recessive lysosomal storage disorder characterized by immune deficiency, facial and skeletal abnormalities, hearing impairment, and intellectual disability. It is caused by mutations in the MAN2B1 gene, leading to deficiency in alpha-mannosidase, a lysosomal enzyme involved in the oligosaccharide degradation pathway. While the exact prevalence of AM in the US is unknown, it has an estimated incidence of 1 in 500,000 live births worldwide. Laboratory indicators of AM often appear shortly after birth, followed by progression of clinical manifestations. While symptoms of AM vary considerably in individual presentations, three clinical subtypes have been identified (mild, moderate, and severe) and are used to guide disease prognosis and management. The current diagnostic algorithm for AM focuses on measuring alpha-mannosidase activity in leukocytes using colorimetry or fluorimetry. An alpha-mannosidase activity level of under 5% suggests AM, and a diagnosis is then confirmed with genetic sequencing.